| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8657303 | Atherosclerosis Supplements | 2017 | 20 Pages |
Abstract
PF does remove a clinically important amount of doxorubicin in a kinetic targeting approach, which can be a useful tool for the increased efficacy and tolerability of therapy with PLD. There were no serious signs of drug toxicity and/or PF-related adverse events.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
M. Blaha, J. Martinkova, M. Lanska, S. Filip, J. Malakova, O. Kubecek, J. Bezouska, J. Spacek,